iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.
iotaSciences, a spin-out from Oxford University specializing in single-cell handling solutions, announced completion of its new single-cell picker instrument on Feb. 6, 2023. The isoPick is designed to provide temperature-controlled handling of single cells during isolation, as well as picking through a workflow guided by touchscreen interfaces.
According to a company press release, the isoPick is intended for cell and gene therapy researchers, as well as the wider single-cell research community, as a means of providing verifiable isolation of single cells with high cell viability and stable single-cell outgrowth. Like the company's other instruments, it is designed to have a small footprint instrument that requires minimal maintenance.
Source: iotaSciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.